SCYX Just Put a Deal-Maker in the CFO Seat — $4.91 Is the Line Between a Base and a Breakdown

Deck: Scynexis handed its only commercial drug to GSK, reverse-split its stock, and loaded up on cash. Now it is swapping finance chiefs right before its next binary catalyst. The option grant tells you the plan; the price decides whether the market plays along.

Scynexis (SCYX) changed its chief financial officer on September 9, and the tape's first answer was a shrug. Ivor Macleod retired after nearly four years in the seat; in stepped Sanjay Subramanian, the biotech CFO who helped steer Inozyme Pharma into a sale to BioMarin. Shares drifted a few percent lower in thin pre-market trade to about $4.70, back under their 50-day moving average (near $4.77) and far below the 200-day (near $5.70), with RSI sitting at 41.

For a chart reader, the resignation letter is less interesting than the compensation sheet stapled to it. Subramanian received an option on 100,000 shares, a ten-year grant, struck at $4.91 — exactly the closing price the day he took over. That number, not the news cycle, is the level this chart now has to answer to.

Why the finance seat matters more than it usually does

The reason a CFO swap deserves attention here is where this company sits: bet-the-company thin. Scynexis is no longer really Scynexis-the-antifungal-company. It transferred the rights to Brexafemme, its only approved product, to GSK in November 2025, took a one-for-eight reverse stock split in late May 2026 to hold its listing price up, and pivoted into rare diseases. The flagship asset now is SCY-770, an unproven experimental drug for ADPKD, a kidney disease, that has not even started its Phase 2 proof-of-concept study — that begins in the fourth quarter of 2026.

That is the clock underneath this headline. The company is a roughly $40-million-market-cap micro-cap holding roughly $72 million in cash and investments as of the end of the first quarter, funded to mid-2029. Five years of runway is the asset; the quarter that starts in three weeks is the date when its whole thesis first has to prove itself in patients.

The signal inside the grant

Management describes the new CFO as a capital-markets and business-development operator, and his history backs that label: CFO and head of business development at Inozyme, where he ran finance, IR, and business development through a sale; earlier CFO of Ocugen; finance roles at Aralez and Bausch Health. Scynexis's own chief executive put it in terms of advancing the pipeline and "driving long-term value".

That profile is the point. A company that was going to quietly grind through five years of clinical trials could hire any competent accountant. Hiring someone whose defining recent act was getting a clinical-stage biotech acquired, and paying him with options struck at the most recent traded close, is a different statement: this management team is positioning for a business-development outcome, and it wants the new finance chief's incentives pinned to the share price today.

Judge that as a signal, not a promise. An inducement grant this size gives a new boss skin in the game; it does not mean a sale is coming. But it is the clearest tell a shareholder can hold that the next big move here may be corporate rather than clinical.

The level that decides

Everything now runs through the $4.91 footprint — the closing price on the CFO's first day and the exact strike of his options. A reclaim of that level with volume expanding would say the market has accepted the reshuffle and the pivot stays alive, opening a path back toward the $5.70 area where the 200-day and heavier overhead supply wait. Lose the recent swing low near $4.60 and the chart goes quiet fast; a micro-cap below its 50-day on shrinking participation does not offer a lot of built support until you look much lower.

The honest read is that this is not a screaming breakout — it is a contest the market has yet to pick a side in. The stock is below both trend-defining averages, and the move down on the announcement was roughly one normal daily range, nothing outsized for this ticker. The setup is a wait-for-confirmation, thin-liquidity one, and that thinness cuts both ways: when a real catalyst hits, it will move in gaps, not gentle waves.

What changes on either side

Scenario	Trigger	Path	Invalidation
Pivot holds	Daily close reclaims ~$4.91 on rising volume	Drift toward $5.70 / 200-day	Failure back under ~$4.60
Corporate spark	Deal / partnership / data announce before Q4	Gaps through $4.91, base breaks higher	No follow-through, back below the zone
Base fails	Close under ~$4.60	Air pocket to lower structural support	Hold of $4.60

The countdown is concrete: SCY-770's Phase 2 start lands in the current quarter, with SCY-247's IV study topline due in the second half of 2026, so the next datapoints that can tilt this chart are weeks away, not years.

Hold $4.60 and the pivot survives into those events; reclaim $4.91 and the base accelerates. Break $4.60 and this becomes a broken base on a micro-cap with no commercial revenue until GSK's relaunch of its former drug possibly pays royalties. The finance chair has changed; the verdict is still sitting at that round of round one at roughly $4.90 — and it has not moved.

Data as of pre-market, September 11, 2026 ET. SCYX is a thinly traded micro-cap; price moves can be abrupt and gaps are common around catalysts. Nothing here is a recommendation to buy or sell.